Jul 15,2020

Theranica Reports Positive Study Results of Nerivio® for Chronic Migraine Patients

Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, today announced that a new peer-reviewed study demonstrates the utility of incorporating Remote Electrical Neuromodulation (REN) into usual care of chronic migraine. The study, published in Pain & Therapy, evaluated 38 patients with chronic migraine and assessed REN's efficacy in treating the symptoms of migraine with or without aura. With Nerivio, 73.7% of participants achieved pain relief at 2 hours and 26.3% were pain free in at least half of their treatments.

CLINICAL STUDY

#connected device

View Analyst & Ambassador Comments
Go to original news
Jul 20,2020

Meaningful digital health engagement is more complicated than how long or often users log in

Sustained engagement is a key metric when determining whether a digital health-based intervention is finding its mark, but the industry has been anything but uniform in determining objective measures of user behavior and their relationship to clinical outcomes. A study published Friday in JAMA Network Open takes another approach and employs machine learning techniques to better describe engagement among 54,604 patients provided a digital health intervention – in this case, an internet-based cognitive behavioral therapy (iCBT) tool for depression and anxiety symptoms developed by SilverCloud Health.

CLINICAL STUDY

#cbt

View Analyst & Ambassador Comments
Go to original news
Jul 21,2020

Lower back pain patients using digital program report significant reduction in pain

The cluster-randomized study, published in the Journal of Pain Research, compared patients using traditional treatment methods to those using a digital program called Rise-uP, which combined electronic case reports, a telehealth consultation aspect, a treatment algorithm for guideline-based clinical decision-making and digital health company Kaia’s app. The study was funded by a German Innovation Fund grant and took place in Southern Germany.

CLINICAL STUDY

#mobile app

#telehealth

View Analyst & Ambassador Comments
Go to original news
Jul 29,2020

Meal logging & lesson completion tied to greater weight loss among Livongo DPP users

A retrospective analysis of more than 2,000 Livongo Diabetes Prevention Program (DPP) participants found an average weight loss of 5.1% from baseline after 12 months, and 6.6% among those who designated as high engagers. The study, conducted by Livongo and published in BMJ Open Diabetes Research & Care, honed in on the relationships between specific program behaviors and program engagement with weight-loss outcomes. Among the 2,037 participants included in the final analysis, 32.3% (n = 658) completed enough lessons to meet the CDC criteria of high engagement. Further analysis of the participants found food logging through Livongo's digital tool to be the greatest predictor of weight loss, followed by lesson completion and physical activity.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Jul 29,2020

Landmark Randomized Controlled Trial Demonstrates Efficacy of Daylight™ Digital Therapeutic in Improving Anxiety

The University of Oxford’s Sleep & Circadian Neuroscience Institute, and Big Health, today announced publication of a randomized controlled trial (RCT) assessing the efficacy and safety of Big Health’s Daylight product in improving symptoms of Generalized Anxiety Disorder (GAD), in the journal Depression and Anxiety. The study found that Daylight significantly reduced symptoms of anxiety in trial participants, as compared to the control group at six weeks after intervention. By week 10 follow-up, 71% of Daylight users in the study achieved remission of GAD, as compared to 33% of those in the control group.

CLINICAL STUDY

#cbt

View Analyst & Ambassador Comments
Go to original news
Jul 31,2020

Digital therapy for insomnia could save NHS millions and improve anxiety and depression symptoms

New report finds use of Sleepio delivers high recovery rates, improve mental health outcomes & could save the NHS £56 million over three years. Patients living with the condition who used Sleepio – a digital sleep improvement programme featuring CBT techniques – had a recovery rate of 56 percent. The report also highlights the findings of an independent study conducted by the Office of Health Economics across nine GP practices in the Thames Valley, which found that Sleepio resulted in a projected saving of £106 per patient over three years. If Sleepio were made available across all clinical commissioning groups (CCGs) in England, this could represent savings for the NHS of as much as £56 million over three years.

CLINICAL STUDY

#cbt

View Analyst & Ambassador Comments
Go to original news
Aug 11,2020

The Acceptability and Impact of the Xploro Digital Therapeutic Platform

There is increasing interest in finding novel approaches to improve the preparation of children for hospital procedures such as surgery, x-rays, and blood tests. A digital therapeutic (DTx) platform (Xploro) was developed with children to provide health information through gamification, serious games, a chatbot, and an augmented reality avatar. This before and after evaluation study aims to assess the acceptability of the Xploro DTx and examine its impact on children and their parent’s procedural knowledge, procedural anxiety, and reported experiences when attending a hospital for a planned procedure.

CLINICAL STUDY

#chatbot

View Analyst & Ambassador Comments
Go to original news
Aug 13,2020

DarioHealth Announces Poster Presentation at the Virtual Association of Diabetes Care and Education Specialists 2020 Annual Conference

DarioHealth today announced that an emerging science industry poster has been accepted for presentation at the virtual Association of Diabetes Care and Education Specialists (ADCES) 2020 Annual Conference, which is being held today, August 13, through August 16, 2020. The poster, entitled, "Impact of Digital Management on Clinical Outcome in Patients with Chronic Conditions: Diabetes and Hypertension," details results from an observational study of 345 participants with hypertensive blood pressure at baseline who utilized the Dario digital therapeutics platform. The paper concludes, "This observational study of a digital therapeutic platform for chronic disease demonstrates improved blood pressure at three months and glycemic control at six months compared to baseline. These findings suggest that digital therapeutics may help sustain behavioral change and play an important role in the management of diabetes and hypertension."

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 20,2020

Sleepio study suggests insomnia treatment could also improve depressive symptoms

The use of cognitive-behavioral therapy interventions, such as Big Health’s Sleepio program, has been found to improve both sleep and mental health in individuals with insomnia and clinically significant depressive symptoms, according to new research published in the Journal of Sleep Research. Although the study was conducted at the University of Oxford, some of the researchers have financial ties to Big Health, and parts of the investigation were funded by Big Health. The study included 3,352 participants as a sub-analysis of data collected from two randomized control trials measuring the effectiveness of Sleepio. Researchers found that addressing sleep problems in individuals who also have depressive symptoms could increase the resolution of depressive symptoms by up to three times.

CLINICAL STUDY

#cbt

View Analyst & Ambassador Comments
Go to original news
Aug 31,2020

Pear Therapeutics Announces Data from Two Studies Evaluating Somryst™ for Chronic Insomnia Presented at Virtual SLEEP 2020

Pear Therapeutics, Inc. announced findings today from two studies of an experimental precursor of Somryst™ (called SHUTi) that evaluated effectiveness to improve sleep outcomes and analyzed user journey data to predict intervention dropout, respectively. The current study evaluated 1,149 Australian adults aged 18-64 years with insomnia and depressive symptoms for the effectiveness of SHUTi vs. an attention-matched control with improving sleep outcomes measured by prospectively entered sleep diary data. Findings from a large-scale randomized controlled trial, Web-delivered CBT for Insomnia Intervention Improves Sleep Among Adults with Insomnia and Depressive Symptoms, show that Somryst can produce lasting improvements in sleep outcomes among adults with insomnia and elevated depressive symptoms.

CLINICAL STUDY

#pdt

#cbt

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY